NCT03091751View on ClinicalTrials.gov

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Hemophilia B
Interventions
DRUG

BeneFIX

BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.

Trial Locations (3)

1000

National Center of Haematology, Sofia

5800

Medical University Pleven, Pleven

9010

"Medical University, University Hospital Sveta Marina,", Varna

All Listed Sponsors
lead

Grifols Biologicals, LLC

INDUSTRY

NCT03091751 - Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B | Biotech Hunter | Biotech Hunter